P03. University Hospitals Leuven, Leuven, Belgium
Principal Investigators: Ignace Vergote

Who whe are: The University Hospitals Leuven are dedicated to research in addition to patient care and education. The Department of Gynaecologic Oncology is a tertiary centre treating >100 new ovarian cancer patients yearly. A large tumourbank has been constructed in the past 15 years with tissue samples from >1600 ovarian tumours. The department currently participates in >25 phase I-II or III trials in ovarian cancer, involving new molecular targeted drugs. The laboratory of experimental gynaecology oncology focuses on translational research on gynaecological cancer, genetic profiling of ovarian tumours is performed in collaboration with the Vesalius Research Centre. For the OCTIPS project, participating team members of the University Hospital Leuven are: (1) Ignace Vergote, M.D., Ph.D., Chair of the Protocol Committee of the European Organisation for Research and Treatment of Cancer-gynaecological Cancer Group (EORTC-GCG), Chairman of the European Network of Gynaecological Oncological Trial groups (ENGOT), Chairman of the Leuven Cancer Institute, and Past-President of the European Society of Gynaecological Oncology (ESGO) and the International Gynecologic Cancer Society (IGCS). (2) Sandrina Lambrechts, M.D., physician performing a fellowship in Gynaecologic Oncology and Ph.D. candidate performing translational research on genetic alterations in ovarian cancer. http://www.uzleuven.be/leuvens-kankerinstituut/dienst-gynaecologie-en-verloskunde
Diether Lambrechts, Ph.D., is professor at the Vesalius Research Centre. His research is focused is on deciphering the genetic basis of ovarian and breast cancer and has access to state-of-the-art genetic technology platforms. www.vrc-lab.be

Our Expertise: Previously we contributed to proteomic analyses of tumour tissues for the prediction of ovarian cancer response within the OVCAD project. Currently, we focus on genetic profiling of tumours: (i) oncogene mutation profiling, including genotyping of hot spot mutations in common cancer genes such as KRAS, B-Raf, P53, and CTNNB1 in large number of tumour DNAs (>1000) using Sequenom Mass ARRAY technology; (ii) determination of copy number alterations on a genome-wide basis using the Illumina iSCAN technology; (iii) whole-genome sequencing of ovarian tumours. We are also leading a multicentre study (Belgian Ovarian Cancer Consortium, BELOCS), collecting germline-DNA of patients with gynaecologic cancers in 12 different Belgian centres. This study contributes to the largest existing international consortium ‘Ovarian Cancer Association Consortium’ (OCAC).

What we will do in OCTIPS: We will provide retrospective collected paired samples and contribute to the collection of prospective paired samples. UZLeuven will lead the workpackage of performing a high quality genomic characterisation of ovarian cancer. Finally, having access to genetic research on samples of patients included in clinical trials testing new molecular targeted drugs, we will be able to correlate the findings with clinical information on therapy response.  

      Ignace Vergote           Sandrina Lambrechts        Diether Lambrechts